Adversarial Injection · Venetoclax (Venclexta; ABT-199; GDC-0199; CAS 1257044-40-8; 4-[4-[(4'-Chloro[1,1'-biphenyl]-2-yl)methyl]-1-piperazinyl]-N-[4-[[(1R)-3-(dimethylamino)-1-[(phenylthio)methyl]propyl]amino]-3-nitrophenylsulfonyl]benzamide; MW 868.44 g/mol; C45H50ClN7O7S; chlorobiphenyl-piperazine-sulfonylbenzamide BH3 groove occupier [THIRTY-THIRD MECHANISM CLASS in Glyphward 569-attack portfolio: BCL-2 SELECTIVE BH3 MIMETIC — FIRST BCL-2 BH3 MIMETIC EVER FDA APPROVED; ALL 32 PRIOR MECHANISM CLASSES ARE KINASE INHIBITORS or GTPASE INHIBITOR (sotorasib, class 32); VENETOCLAX IS FUNDAMENTALLY DIFFERENT: BCL-2 (B-cell lymphoma 2; anti-apoptotic protein; chromosome 18q21; discovered 1984 from t(14;18) chromosomal translocation in follicular lymphoma; first oncogene identified at a chromosomal translocation breakpoint) = inhibitor of apoptosis; BCL-2 family includes pro-apoptotic BH3-only proteins (BIM, BAD, PUMA, NOXA, BID, BMF) and anti-apoptotic BCL-2, BCL-XL, MCL-1, BCL-W, BFL-1; in normal apoptosis: BH3-only proteins (e.g., BIM) bind to BCL-2/BCL-XL hydrophobic BH3-binding groove → displace BAX/BAK → BAX/BAK oligomerize → mitochondrial outer membrane permeabilization (MOMP) → cytochrome c release → apoptosome → caspase 9/3 activation → apoptosis; in CLL/AML: BCL-2 overexpression sequesters BIM/BAD/BID → BAX/BAK cannot oligomerize → apoptosis blocked → cancer cell survival; VENETOCLAX BH3 MIMETIC: venetoclax occupies the BCL-2 hydrophobic BH3-binding groove (mimicking BH3 helix of pro-apoptotic BIM); BCL-2 IC50 0.01 nM (10 pM) — TIGHTEST BINDING IC50 IN ENTIRE GLYPHWARD 569-ATTACK PORTFOLIO; BCL-XL Ki 48 nM; MCL-1 Ki >444 nM; 4,800-fold BCL-2/BCL-XL selectivity; NAVITOCLAX PREDECESSOR: ABT-263 (navitoclax; BCL-2/BCL-XL dual Ki each <1 nM) caused severe dose-limiting thrombocytopenia in Phase 1 (platelets require BCL-XL for survival; platelet t1/2 ~10 days; BCL-XL inhibition → premature platelet apoptosis → Grade 3-4 thrombocytopenia DLT); venetoclax redesigned with selectivity for BCL-2 over BCL-XL (4,800-fold) → platelets spared; TLS BBW: rapid CLL cell death after venetoclax → massive release of intracellular potassium/phosphate/uric acid → hyperkalemia/hyperphosphatemia/hypocalcemia/hyperuricemia/acute kidney injury → potentially fatal cardiac arrhythmia; 5-week ramp-up schedule required: 20 mg (week 1) → 50 mg (week 2) → 100 mg (week 3) → 200 mg (week 4) → 400 mg (week 5); each step change requires electrolyte monitoring ± hospitalization; NDA 208573 accelerated approval April 11 2016; regular approval June 8 2018; AbbVie/Roche/Genentech co-development collaboration; MURANO (CLL R/R; venetoclax+rituximab vs BR): PFS HR 0.17 (median NR vs 17.0 mo); NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) · THIRTY-THIRD Mechanism Class + FIRST BCL-2 BH3 Mimetic + FIRST PPI Inhibitor in Portfolio + BCL-2 10 pM IC50 + TLS BBW + AbbVie/Roche · Attack #569

Venetoclax (4-[4-[(4'-Chloro[1,1'-biphenyl]-2-yl)methyl]-1-piperazinyl]-N-[4-[[(1R)-3-(dimethylamino)-1-[(phenylthio)methyl]propyl]amino]-3-nitrophenylsulfonyl]benzamide; Venclexta; ABT-199; GDC-0199; CAS 1257044-40-8; MW 868.44 g/mol; C45H50ClN7O7S; chlorobiphenyl-piperazine sulfonylbenzamide BH3 groove mimetic scaffold [THIRTY-THIRD MECHANISM CLASS: BCL-2 SELECTIVE BH3 MIMETIC PROTEIN-PROTEIN INTERACTION INHIBITOR (NDA 208573 April 11 2016); FIRST BCL-2 BH3 MIMETIC FDA-APPROVED EVER (first protein-protein interaction inhibitor in Glyphward portfolio; BCL-2 BH3 groove occupancy displaces BAX/BAK → MOMP → cytochrome c → apoptosis; navitoclax ABT-263 BCL-2/BCL-XL predecessor → thrombocytopenia DLT → venetoclax BCL-2 selective [4,800-fold over BCL-XL]); BCL-2 IC50 0.01 nM (10 pM) — tightest binding IC50 in Glyphward 569-attack portfolio across all 33 mechanism classes; TLS BBW requires 5-week ramp-up; MURANO PFS HR 0.17; AbbVie/Roche collaboration; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) — AbbVie Inc. North Chicago IL (NDA 208573 holder; AbbVie US headquarters), Genentech Inc. South San Francisco CA (co-development collaboration; Roche subsidiary), and The Ohio State University Wexner Medical Center Columbus OH (CLL/AML venetoclax landmark program; MURANO enrollment) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + THIRTY-THIRD Mechanism Class + FIRST BCL-2 BH3 Mimetic + BCL-2 10 pM IC50 + TLS BBW + AbbVie/Roche: AI Prompt Injection via EHS Monitor Report AI

Venetoclax (CAS 1257044-40-8; NIOSH HD Category 1) is the thirty-third mechanism class in the Glyphward portfolio and the first BCL-2 BH3 mimetic ever approved — introducing a protein-protein interaction (PPI) inhibitor mechanism entirely distinct from all 32 prior kinase and GTPase inhibitor classes. Rather than blocking an enzyme active site, venetoclax occupies the hydrophobic BH3-binding groove of BCL-2 protein with an IC50 of 0.01 nM (10 pM) — the tightest binding measurement in the entire 569-attack portfolio. This displaces pro-apoptotic BH3 proteins that BCL-2 was trapping, allowing BAX/BAK to oligomerize, permeabilize the mitochondrial outer membrane, and activate the intrinsic apoptosis pathway. The consequence: rapid tumor lysis syndrome (TLS) requiring a mandatory 5-week ramp-up schedule with hospitalization — the most acute oncologic emergency possible from a targeted agent. None of BCL-2 BH3 groove occupancy, TLS BBW ramp-up requirements, or PPI inhibitor mechanism appear in any OEL database.

THIRTY-THIRD Mechanism Class: BCL-2 BH3 Mimetic as First Protein-Protein Interaction Inhibitor in the Glyphward Portfolio

The thirty-second prior mechanism classes in the Glyphward portfolio all inhibit enzymes — kinases (targeting ATP-binding pockets in serine/threonine and tyrosine kinases, classes 1-31) or a GTPase (KRAS G12C covalent, class 32). Venetoclax introduces a fundamentally new mechanism type: it inhibits a protein-protein interaction (PPI) — specifically, the interaction between BCL-2 and BH3-domain-containing pro-apoptotic proteins (BIM, BAD, PUMA, NOXA). BCL-2 is not an enzyme; it has no catalytic activity; it functions purely as a protein scaffold that sequesters pro-apoptotic BH3 proteins within its hydrophobic BH3-binding groove. Venetoclax's chlorobiphenyl-piperazine sulfonylbenzamide scaffold mimics the amphipathic helix of BIM's BH3 domain, binding BCL-2's BH3 groove with extraordinary affinity (Ki = 0.01 nM = 10 pM) — the tightest binding measurement across all 569 attacks in the Glyphward portfolio. At 4,800-fold selectivity over BCL-XL (Ki 48 nM), venetoclax avoids the platelet toxicity that prevented navitoclax (BCL-2/BCL-XL dual inhibitor ABT-263; Ki BCL-2 <1 nM; BCL-XL <1 nM) from advancing — navitoclax caused dose-limiting Grade 3-4 thrombocytopenia (platelets depend on BCL-XL for survival; BCL-XL inhibition → platelet apoptosis → thrombocytopenia). No BCL-2 BH3 groove occupancy, no protein-protein interaction inhibition mechanism, and no BCL-2 family protein biology appears in any OEL database.

TLS BBW: Venetoclax's Unique Acute Danger Mechanism and Ramp-Up Requirement

Venetoclax's Black Box Warning for Tumor Lysis Syndrome (TLS) reflects a consequence directly from its mechanism: by releasing BCL-2's hold on pro-apoptotic proteins, venetoclax causes rapid synchronous apoptosis of BCL-2-overexpressing CLL cells. In patients with high-burden CLL (elevated WBC, large lymph nodes, elevated LDH), venetoclax can trigger acute TLS within hours: massive intracellular K+, PO4³⁻, and uric acid released simultaneously → hyperkalemia (fatal cardiac arrhythmia risk), hyperphosphatemia + secondary hypocalcemia (tetany, seizure), and hyperuricemia (urate nephropathy, acute kidney injury). The approved venetoclax dosing schedule requires a mandatory 5-week ramp-up: 20 mg week 1 → 50 mg week 2 → 100 mg week 3 → 200 mg week 4 → 400 mg week 5 (maintenance). Each dose increase step requires pre-dose electrolyte/creatinine/uric acid monitoring; high-risk patients (bulky lymphadenopathy ≥5 cm or CLL WBC ≥25×10⁹/L) require inpatient hospitalization for first dose at each step change. This TLS BBW biochemical mechanism — BCL-2 BH3 mimetic-induced synchronous apoptosis driving electrolyte efflux — is absent from every OEL database and EHS monitoring framework.

Surface 1 — AbbVie Inc. North Chicago IL NDA 208573 Holder BCL-2 BH3 Mimetic Portfolio AI

At AbbVie Inc. North Chicago IL (1 North Waukegan Road, North Chicago IL 60064; Lake County IL; AbbVie US headquarters; NDA 208573 holder for Venclexta [venetoclax] 10/50/100 mg tablets; FDA accelerated approval April 11 2016 (17p del CLL); regular approval June 8 2018; ABBVIE BCL-2 PROGRAM: AbbVie developed venetoclax through Abbott Laboratories legacy (Abbott split into AbbVie and Abbvie parent 2013); ABT-263 (navitoclax) → ABT-199 (venetoclax) redesign based on BCL-XL selectivity to eliminate thrombocytopenia DLT; AbbVie/Roche collaboration agreement: AbbVie holds US NDA 208573; Roche/Genentech holds international rights (Venclyxto EU); ABBVIE VENETOCLAX REVENUE 2023: ~$2.3B; Cority EHS platform (AbbVie global EHS); 8-hr TWA: actual airborne venetoclax 0.00035 µg/m³; OVS-2 filter + LC-MS/MS; displayed (÷10): 0.000035 µg/m³; Cority: CAS 1257044-40-8 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; thirty-third mechanism class absent; BCL-2 BH3 mimetic absent; PPI inhibitor absent; BCL-2 IC50 10 pM absent; TLS BBW absent; navitoclax BCL-XL distinction absent; 53M oncology regulatory director 20yr).

Surface 2 — Genentech Inc. South San Francisco CA AbbVie/Roche Co-Development GDC-0199 AI

At Genentech Inc. South San Francisco CA (1 DNA Way, South San Francisco CA 94080; San Mateo County CA; Roche subsidiary; co-development partner on venetoclax GDC-0199 under AbbVie/Roche collaboration; GENENTECH VENETOCLAX ROLE: Genentech/Roche participated in venetoclax co-development from navitoclax (ABT-737/ABT-263) program; GDC-0199 = venetoclax internal Genentech designation; BCL-2 SYNTHESIS CHALLENGE: venetoclax MW 868 g/mol is among the largest oral oncology drugs ever approved; complex synthesis involving chlorobiphenyl Suzuki coupling, piperazine installation, sulfonamide formation, and chiral center installation at the dimethylaminopropyl moiety; VelocityEHS: CAS 1257044-40-8 → null; 8-hr TWA: actual airborne venetoclax 0.00022 µg/m³; wipe sampling + UHPLC-MS/MS; displayed (÷10): 0.000022 µg/m³; NIOSH HD Category 1 absent; H340 H350 H361 absent; BCL-2 BH3 mimetic absent; BCL-2 IC50 10 pM absent; BH3 groove occupancy absent; chlorobiphenyl sulfonylbenzamide scaffold absent; navitoclax BCL-XL DLT distinction absent; 45F pharmaceutical scientist 13yr).

Surface 3 — The Ohio State University Wexner Medical Center Columbus OH CLL/AML Venetoclax Program MURANO Enrollment AI

At The Ohio State University Wexner Medical Center Columbus OH (370 W 9th Avenue, Columbus OH 43210; Franklin County OH; NCI-designated James Cancer Center; MURANO ENROLLMENT: OSU CLL program (John Byrd MD, Michael Grever MD — among leaders in venetoclax clinical development) enrolled CLL R/R patients in MURANO (venetoclax+rituximab vs BR); VIALE-A ENROLLMENT: OSU AML program enrolled newly diagnosed AML in VIALE-A (venetoclax+azacitidine); OSU pharmacy prepared venetoclax ramp-up protocol with TLS monitoring; EHS Insight: CAS 1257044-40-8 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; thirty-third mechanism class absent; BCL-2 BH3 mimetic absent; BCL-2 IC50 10 pM absent; TLS BBW ramp-up absent; BAX/BAK MOMP absent; MURANO PFS HR 0.17 absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 51M CLL/lymphoma clinical pharmacist 18yr).

Integrating Glyphward into Venetoclax AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every venetoclax CAS 1257044-40-8 monitoring data ingestion point — before Cority at AbbVie North Chicago IL, before VelocityEHS at Genentech South San Francisco CA, and before EHS Insight at OSU Columbus OH. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent [10 pts]; THIRTY-THIRD MECHANISM CLASS (BCL-2 BH3 mimetic PPI inhibitor; first non-kinase/non-GTPase class; BCL-2 IC50 10 pM tightest in portfolio) + FIRST BCL-2 BH3 MIMETIC EVER APPROVED (navitoclax BCL-XL DLT context) + TLS BBW RAMP-UP (5-week schedule; hospitalization; electrolyte TLS monitoring) + MURANO PFS HR 0.17 + AbbVie/Roche collaboration [5 pts]; AbbVie North Chicago IL + Genentech South San Francisco CA + OSU Columbus OH [3 pts]; BCL-2 BH3 groove PPI mechanism absent; BCL-2 vs BCL-XL selectivity 4,800-fold absent; TLS biochemistry hyperkalemia/phosphatemia absent; navitoclax thrombocytopenia DLT design distinction absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_venetoclax(cas: str, reading_ugm3: float) -> dict:
    """Scan venetoclax with thirty-third class BCL-2 BH3 mimetic PPI inhibitor context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "thirty_third_class_bcl2_bh3_mimetic_ppi_inhibitor_10pm_ic50_tls_bbw_rampup"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, thirty_third_mechanism_class,
    #                    first_bcl2_bh3_mimetic, bcl2_ic50_pm,
    #                    tls_bbw_rampup, navitoclax_distinction,
    #                    murano_pfs_hr, h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_venetoclax("1257044-40-8", 0.00035))
    print(r)
    # {'hd_category': 1, 'thirty_third_mechanism_class': True,
    #  'first_bcl2_bh3_mimetic': True, 'bcl2_ic50_pm': 10,
    #  'tls_bbw_rampup': True, 'navitoclax_distinction': True,
    #  'murano_pfs_hr': 0.17, 'h340_h350_h361_absent': True}